Drugs / ARCT-154
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05037097 | Aug 2021 → Dec 2023 | COVID-19 | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05012943 | Aug 2021 → Jan 2023 | — | Vinbiocare Biotechnology Joint Stock Company | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | CSL Behring | CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster csl.com ↗ |
| 2023-11-28 | CSL Behring | Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults csl.com ↗ |
| 2023-09-05 | CSL Behring | Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19 csl.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARCT-154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05012943 ↗ |
| Modality | Small activating RNA (saRNA) | “ARCT-154 Self-Amplifying RNA Vaccine” NCT05012943 ↗ |